Ten years ago, medicinal cannabis was legalised in Australia. At the time, the conversation was cautious. The science was emerging. The regulatory frameworks were being built almost in real time. There were more questions than answers. In regional New South Wales, in a city better known for its agriculture, winters and university campus than for pharmaceuticals, something significant began quietly. Armidale is where it all started.
Australian Natural Therapeutics Group (ANTG) was one of the first Australian companies to step into the newly legal medicinal cannabis sector. From the outset, the decision was deliberate: this would not be an import-reliant trading model. It would be research, cultivation and manufacturing on Australian soil, to pharmaceutical standards. And it would happen in Armidale.
Why Armidale? Armidale is a well-established agricultural and education hub. Generations of farming expertise coexist with high-level scientific capability through the University of New England. That combination matters. Medicinal cannabis, when grown to pharmaceutical standards, is not simply horticulture. It is controlled-environment agriculture, quality systems, data, plant science, compliance and manufacturing discipline. It requires both hands in the soil and eyes on the laboratory results. Armidale offered both. It also offered something else: community. A regional workforce prepared to learn, adapt and participate in an emerging industry, from skilled scientific roles to operational and manufacturing positions.
Setting a benchmark
ANTG became the first Australian medicinal cannabis company to receive GACP, Good Agricultural and Collection Practice certification. That milestone did more than validate cultivation standards. It enabled ANTG to become the first Australian company to export commercial medicinal cannabis flower to the European market. For a regional Australian city, that was no small moment. It signalled that Armidale was not just participating in a new industry, it was helping define it.
Why domestic production matters
Over the past decade, Australia’s medicinal cannabis sector has grown rapidly. Imports have increased. Access pathways have evolved. Prescribing has expanded. But growth brings risk. An industry heavily reliant on imports can be vulnerable to supply chain disruption, regulatory divergence and quality variability. For a medicine used by patients with chronic or complex conditions, supply continuity and product integrity are not optional.
Domestic cultivation and manufacturing strengthen healthcare sovereignty
Producing in Australia means operating within Australia’s regulatory framework, overseen by the Therapeutic Goods Administration. It means tighter oversight, local accountability, and investment that stays in regional communities. It positions Armidale not only as a site of agricultural production, but as part of Australia’s national healthcare resilience.
From plant to prescription
Medicinal cannabis has become more visible over the past decade, as a regulated therapeutic option prescribed by a medical practitioner when clinically appropriate. Cannabis contains more than 100 cannabinoids. The two most recognised are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC can assist with pain, nausea and muscle spasticity, but it is also intoxicating and can impair coordination and concentration. CBD is non-intoxicating and generally better tolerated, with potential applications in inflammation, anxiety and certain neurological conditions. These differences are clinically and legally significant. In Australia, products are regulated according to their THC and CBD content, with stricter controls applied to THC-containing medicines. It’s important to point out that medicinal cannabis remains an unapproved medicine and not considered a first-line therapy. It is not available over the counter. It is prescribed under regulated pathways, following assessment of diagnosis, treatment history and risk factors. The goal is symptom relief and improved quality of life, not intoxication.
A decade of learning
Ten years on, medicinal cannabis in Australia is still evolving. The evidence base is strong for some conditions and emerging for others. Clinical practice continues to mature. Education remains essential for both doctors and patients. For regional communities like Armidale, the industry represents more than cultivation. It represents:
- Skilled employment in advanced agriculture and manufacturing
- Collaboration between industry and academia
- Export capability from regional Australia
- Sovereign production of a regulated therapeutic good
Most importantly, it represents measured progress. Medicinal cannabis should neither be dismissed nor over-promoted. Its value lies in careful, individualised use within a broader healthcare plan. And in Armidale, it began with a decision. If Australia was going to build this industry, it should grow it properly, from the ground up.
